Skip to main content
Journal cover image

Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.

Publication ,  Journal Article
Ajani, JA; Goudeau, P; Levin, B; Faintuch, JS; Abbruzzese, JL; Boman, BM; Kanojia, MD
Published in: Cancer Chemother Pharmacol
1989

The purpose of this study was to evaluate the response rate, methotrexate plasma levels, and toxicity of a three-drug regimen in patients with gastric carcinoma. A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated with Adriamycin, methotrexate, and 5-fluorouracil (AMF). Adriamycin and methotrexate were given as i.v. infusions on day 1; 24 h following methotrexate administration, patients received an i.v. infusion of 5-fluorouracil concomitantly with oral leukovorin factor (given over 48 h). Methotrexate levels were monitored regularly in all patients, and courses were repeated every 3 weeks. The median dose levels per course were 50 mg/m2 (range, 40-60 mg/m2) for Adriamycin, 1,000 mg/m2 (range, 650-1,250 mg/m2) for 5-fluorouracil, and 500 mg/m2 (range, 160-625 mg/m2) for methotrexate. Of 36 evaluable patients, 8 (22%) achieved an objective response, including 1 complete remission. Stable disease was noted in 11 patients and a minor tumor regression occurred in 1. The median survival duration of all patients was 6 months (range, 2-31+ months). AMF was well tolerated; toxicities were mild to moderate, most frequently involving nausea and vomiting, mucositis, and neutropenia with or without fever. There was no death directly attributable to chemotherapy. Although the AMF regimen used a well-documented preclinical concept of synergism between methotrexate and 5-fluorouracil, response and survival results suggest a modest activity of this combination in patients with gastric cancer. Better preclinical models are necessary for the development of effective combination chemotherapy.

Duke Scholars

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1989

Volume

24

Issue

1

Start / End Page

41 / 44

Location

Germany

Related Subject Headings

  • Stomach Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Methotrexate
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Drug Evaluation
  • Doxorubicin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ajani, J. A., Goudeau, P., Levin, B., Faintuch, J. S., Abbruzzese, J. L., Boman, B. M., & Kanojia, M. D. (1989). Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol, 24(1), 41–44. https://doi.org/10.1007/BF00254103
Ajani, J. A., P. Goudeau, B. Levin, J. S. Faintuch, J. L. Abbruzzese, B. M. Boman, and M. D. Kanojia. “Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.Cancer Chemother Pharmacol 24, no. 1 (1989): 41–44. https://doi.org/10.1007/BF00254103.
Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, et al. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol. 1989;24(1):41–4.
Ajani, J. A., et al. “Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.Cancer Chemother Pharmacol, vol. 24, no. 1, 1989, pp. 41–44. Pubmed, doi:10.1007/BF00254103.
Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanojia MD. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol. 1989;24(1):41–44.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1989

Volume

24

Issue

1

Start / End Page

41 / 44

Location

Germany

Related Subject Headings

  • Stomach Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Methotrexate
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Drug Evaluation
  • Doxorubicin